Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04533503 · ClinicalTrials.gov registry record
Vis-Rx Post-Market Evaluation
A clinical trial, sponsored by Gentuity.
- Completed
- Registry status
- 257
- Enrollment target
NCT04533503: Completed study, sponsored by Gentuity.
NCT04533503 is a clinical trial that has completed, run by Gentuity. The registered enrollment target is 257 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04533503 has completed, sponsored by Gentuity.
- COMPLETED
- Registry status
- 257 participants
- Enrollment target
Study Summary
Post-market clinical evaluation of the Gentuity High-Frequency Optical Coherence Tomography (HF-OCT) System and the Vis-Rx Micro-Imaging Catheter for use in Percutaneous Coronary Intervention (PCI) procedures.
Primary Outcome
Operator evaluation of performance via Likert scale
Interventions
- DEVICE HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2023-01-25 |
What the finished NCT04533503 record still lists
NCT04533503 is an observational study that tracks outcomes without assigning an intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter is the first listed.
NCT04533503 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04533503 about?
NCT04533503 is a clinical study titled "Vis-Rx Post-Market Evaluation". Post-market clinical evaluation of the Gentuity High-Frequency Optical Coherence Tomography (HF-OCT) System and the Vis-Rx Micro-Imaging Catheter for use in Percutaneous Coronary Intervention (PCI) procedures.
What is the current status of trial NCT04533503?
This trial is currently completed. The enrollment target is 257 participants. The study started on 2021-02-22. Estimated completion is 2023-01-25.
What interventions are being tested in trial NCT04533503?
The interventions under investigation include: HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter (DEVICE).
Who is sponsoring clinical trial NCT04533503?
This trial is sponsored by Gentuity, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI